Trident there is always recourseParticularly in our excessively litigious country. Telesta could always invoke a case based on precedent with the current Endo offering but that would rub the wrong wound. That panel, for all its blatant shortcomings, was the panel that the FDA assigned. Yet, digressing and using the same precedent and corresponding playbook, I would re engage the FDA for the same market treatment Valstar seek s to serve, however limited it may be. My/Our understanding is that MCNA trounces Valstar in this small but potentially mutating market segment. I'm still semi despondent with the overtly discriminating intellectual posture of our Adcomm, but tomorrow is the next step.